Clinical Trials Directory

Trials / Unknown

UnknownNCT02838940

Preventive Antibiotic Serum Levels During Caesarean Section

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
250 (estimated)
Sponsor
Tel-Aviv Sourasky Medical Center · Other Government
Sex
Female
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

Background Preventive antibiotic treatment before performing invasive procedures is a basic element in preventing infections. The essence of preventive antibiotic treatment is strengthening the defense mechanisms of the immune system by preserving a certain drug levels in the blood. The timing of giving the antibiotics is very important. Several research groups have tried to check the levels of Cefazolin (the most common antibiotics in the field of obstetrics) in serum and adipose tissue in women during cesarean. These groups presented conflicting research results. OBJECTIVE This study will discuss the preventive antibiotic treatment levels accepted prior cesareans, to determine: 1. What are the factors affecting the level of drug in the blood? 2. Is there a fixed time which beyond it, blood drug levels are below the MIC(Minimal Inhibitory Concentration)? 3. Is the provision of usual preventive care also addresses the situations of metabolic disorder?

Detailed description

Background Preventive antibiotic treatment before performing invasive procedures is a basic element in preventing infections. The essence of preventive antibiotic treatment is strengthening the defense mechanisms of the immune system by preserving a certain drug levels in the blood. The timing of giving the antibiotics is very important. Several research groups have tried to check the levels of Cefazolin (the most common antibiotics in the field of obstetrics) in serum and adipose tissue in women during cesarean. These groups presented conflicting research results. OBJECTIVE This study will discuss the preventive antibiotic treatment levels accepted prior cesareans, to determine: 1. What are the factors affecting the level of drug in the blood? 2. Is there a fixed time which beyond it, blood drug levels are below the MIC(Minimal Inhibitory Concentration)? 3. Is the provision of usual preventive care also addresses the situations of metabolic disorder? PATIENTS \& METHODS Women that meet the inclusion criteria and are about to undergo cesarean in different indications, in elective and urgent way. 1. Before performing TIMEOUT outside the surgery room, The investigators will explanation about the process and purpose of the study, and informed consent will be obtained. 2. Prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams. 3. With the beginning of the first incision in the skin, first blood sample will be taken to test levels of antibiotics in serum. 4. Second blood sample to test drug levels in serum will be taken while closing the surgical incision in the skin at the end of the operation. 5. The continuation of post surgery recovery process will be as usual, in accordance with departmental protocols. With the results of tissue and serum samples, segmentation which compares the drug levels in the different tissues will be performed.Also, the correlation between drug levels in women with different BMI and morbidities that may cause measurable or not pharmacokinetic changes will be examined.

Conditions

Interventions

TypeNameDescription
PROCEDUREBlood samples.At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test. Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation.
DRUGCefazolinAccording to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.

Timeline

Start date
2016-08-01
Primary completion
2019-08-01
Completion
2019-08-01
First posted
2016-07-20
Last updated
2016-07-20

Source: ClinicalTrials.gov record NCT02838940. Inclusion in this directory is not an endorsement.